Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19-28z/IL-18 CAR T Cells in R/R ALL
NCT06287528Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2024
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of huCART19-IL18 in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Toxicity as determined by CTCAE, version 5.0 at 4 weeks. Started Feb 2024; status: recruiting.
02
Drugs
huCART19-IL18
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06287528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287528.